Abstract: P702
Type: Poster Sessions
Abstract Category: Clinical aspects of MS - Clinical assessment tools
Introduction: Users' acceptance is essential for the implementation of new digital tools in routine medical care of patients living with multiple sclerosis (PwMS). MSCopilot (MSC) is a CE-marked software for the self-assessment of PwMS covering 4 measures: walking perimeter (WP), upper-limb dexterity, cognition and low-contrast visual acuity (LCVA). This application aims at providing clinically validated remote monitoring for PwMS and clinicians. MSC potential benefits are: i) Standardisation of tests with automatic calculation of individual and composite z-scores, ii) Comparability of results with Multiple Sclerosis Functional Composite (MSFC), iii) Accurate measurement of the walking perimeter, in PwMS' real-life, and iv) saving time during medical visits
Objective: This study assessed the potential of MSC for the digital self-assessment of MS-related disabilities in clinical practice (NCT03148938)
Methods: a total of 146 PwMS fulfilling the 2010 revised McDonald criteria and 76 healthy controls (HC) will be recruited in 11 French centres, performing successively MSC digital tests (e.g. WP, dexterity, cognition and LCVA) and standard tests [EDSS, Nine-Hole Peg Test, Symbol Digit Modalities Test (SDMT), Timed 25-Foot Walk (T25FW) and Sloan Low Contrast Letter Acuity Test (SLCLAT)]. 60 PwMS will be assessed one month later for test-retest reliability. Satisfaction is evaluated via anonymised self-reported questionnaires.
Results: 48 PwMS surveys were collected. Mean (median) duration of digital tests, 48min (40min) and standard tests, 46min (30min) were equivalent (p=0.81). The duration of digital tests was found rather short by 87% of PwMS vs 70% for the standard test (p=0.046); 87% of PwMS were favourable to the use of a mobile app as part of medical care and 78% believed that using MSC once a month would be easy to perform. Moreover, 93% felt that the data collected between consultations could improve the management of their disease, 87% preferred digital over standard evaluations and 97% would recommend MSC to other PwMS. Inclusions will end by the first of June, and final results will be presented during the meeting.
Conclusion: MSC is suitable for the self-assessment of MS disabilities in real life, with excellent acceptance by PwMS.
Disclosure: This project was sponsored by Ad Scientiam SAS and has received a grant from Roche SAS France.
E.Maillart has received consulting and lecturing fees, travel grants, from ad Scientiam, Biogen Idec, Genzyme, Novartis, Merck Serono, Roche, Sanofi, and Teva Pharma, and research
support from Novartis and Roche.
P. Labauge: Honoraria and consulting fees from Biogen,Sanofi-Genzyme, Bayer, Novartis, Teva, Merck-Serono, Roche and Medday. Research supports from Biogen, Novartis, Sanofi-Genzyme, Roche and Medday.
M. Cohen, P Gallien, C Donze, A Maarouf, T Moreau: nothing to disclose
S. Vukusic has received consulting and lecturing fees, travel grants and research support from Biogen, Celgene, Genzyme, Medday, Merck Serono, Novartis, Roche, Sanofi Aventis and Teva Pharma.
B Bourre serves on scientific advisory board for Merck Serono and has received funding for travel and honoraria from Biogen Idec, Merck Serono, Novartis, Sanofi-Genzyme, Roche and Teva.S. Bieuvelet, F. Bertillot are employees of Ad Scientiam
S. Zinaï is employee of, and stakeholder in, Ad Scientiam
A Tourbah has received consulting and lecturing fees, travel grants and research support from Medday, Biogen, Sanofi-Genzyme, Novartis, Merck Serono, Teva Pharma, and Roche
Abstract: P702
Type: Poster Sessions
Abstract Category: Clinical aspects of MS - Clinical assessment tools
Introduction: Users' acceptance is essential for the implementation of new digital tools in routine medical care of patients living with multiple sclerosis (PwMS). MSCopilot (MSC) is a CE-marked software for the self-assessment of PwMS covering 4 measures: walking perimeter (WP), upper-limb dexterity, cognition and low-contrast visual acuity (LCVA). This application aims at providing clinically validated remote monitoring for PwMS and clinicians. MSC potential benefits are: i) Standardisation of tests with automatic calculation of individual and composite z-scores, ii) Comparability of results with Multiple Sclerosis Functional Composite (MSFC), iii) Accurate measurement of the walking perimeter, in PwMS' real-life, and iv) saving time during medical visits
Objective: This study assessed the potential of MSC for the digital self-assessment of MS-related disabilities in clinical practice (NCT03148938)
Methods: a total of 146 PwMS fulfilling the 2010 revised McDonald criteria and 76 healthy controls (HC) will be recruited in 11 French centres, performing successively MSC digital tests (e.g. WP, dexterity, cognition and LCVA) and standard tests [EDSS, Nine-Hole Peg Test, Symbol Digit Modalities Test (SDMT), Timed 25-Foot Walk (T25FW) and Sloan Low Contrast Letter Acuity Test (SLCLAT)]. 60 PwMS will be assessed one month later for test-retest reliability. Satisfaction is evaluated via anonymised self-reported questionnaires.
Results: 48 PwMS surveys were collected. Mean (median) duration of digital tests, 48min (40min) and standard tests, 46min (30min) were equivalent (p=0.81). The duration of digital tests was found rather short by 87% of PwMS vs 70% for the standard test (p=0.046); 87% of PwMS were favourable to the use of a mobile app as part of medical care and 78% believed that using MSC once a month would be easy to perform. Moreover, 93% felt that the data collected between consultations could improve the management of their disease, 87% preferred digital over standard evaluations and 97% would recommend MSC to other PwMS. Inclusions will end by the first of June, and final results will be presented during the meeting.
Conclusion: MSC is suitable for the self-assessment of MS disabilities in real life, with excellent acceptance by PwMS.
Disclosure: This project was sponsored by Ad Scientiam SAS and has received a grant from Roche SAS France.
E.Maillart has received consulting and lecturing fees, travel grants, from ad Scientiam, Biogen Idec, Genzyme, Novartis, Merck Serono, Roche, Sanofi, and Teva Pharma, and research
support from Novartis and Roche.
P. Labauge: Honoraria and consulting fees from Biogen,Sanofi-Genzyme, Bayer, Novartis, Teva, Merck-Serono, Roche and Medday. Research supports from Biogen, Novartis, Sanofi-Genzyme, Roche and Medday.
M. Cohen, P Gallien, C Donze, A Maarouf, T Moreau: nothing to disclose
S. Vukusic has received consulting and lecturing fees, travel grants and research support from Biogen, Celgene, Genzyme, Medday, Merck Serono, Novartis, Roche, Sanofi Aventis and Teva Pharma.
B Bourre serves on scientific advisory board for Merck Serono and has received funding for travel and honoraria from Biogen Idec, Merck Serono, Novartis, Sanofi-Genzyme, Roche and Teva.S. Bieuvelet, F. Bertillot are employees of Ad Scientiam
S. Zinaï is employee of, and stakeholder in, Ad Scientiam
A Tourbah has received consulting and lecturing fees, travel grants and research support from Medday, Biogen, Sanofi-Genzyme, Novartis, Merck Serono, Teva Pharma, and Roche